

Alessandro Busca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/172854/publications.pdf>

Version: 2024-02-01

100
papers

5,129
citations

196777

29
h-index

104191

69
g-index

100
all docs

100
docs citations

100
times ranked

8857
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. <i>Blood Advances</i> , 2022, 6, 2427-2433.	2.5	46
2	COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. <i>Blood</i> , 2022, 139, 1588-1592.	0.6	70
3	When Viruses Meet Fungi: Tackling the Enemies in Hematology. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 184.	1.5	0
4	Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. <i>Lancet Haematology</i> , 2022, 9, e361-e373.	2.2	25
5	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. <i>Blood Advances</i> , 2022, 6, 3870-3874.	2.5	8
6	High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 1537-1547.	1.0	10
7	SARS-CoV-2 infection in a stem cell transplant recipient grafted from a SARS-CoV-2-positive donor. <i>Bone Marrow Transplantation</i> , 2022, 57, 1604-1606.	1.3	3
8	Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103203.	2.0	4
9	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. <i>Hemato</i> , 2021, 2, 79-88.	0.2	0
10	EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19. <i>HemaSphere</i> , 2021, 5, e612.	1.2	29
11	Letemovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience. <i>Frontiers in Oncology</i> , 2021, 11, 740079.	1.3	19
12	Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021. <i>Cancers</i> , 2021, 13, 5075.	1.7	9
13	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	6.9	189
14	Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 805514.	1.8	7
15	Developments in identifying and managing mucormycosis in hematologic cancer patients. <i>Expert Review of Hematology</i> , 2020, 13, 895-905.	1.0	6
16	Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEM-12B study). <i>Mycoses</i> , 2020, 63, 1094-1100.	1.8	6
17	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	2.2	430
18	CMV retinitis in a stem cell transplant recipient treated with foscarnet intravitreal injection and CMV specific immunoglobulins. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072097565.	1.1	8

#	ARTICLE	IF	CITATIONS
19	The Management of Hematologic Patients with Bloodstream Infections Due to Multi-Drug Resistant Bacteria: Where Do We Stand? From Antibacterial Prophylaxis to the Treatment of Septic Shock. <i>Hemato</i> , 2020, 1, 60-76.	0.2	3
20	Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096191.	1.1	9
21	Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis. <i>Mycoses</i> , 2020, 63, 900-910.	1.8	10
22	An update on the treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. <i>Expert Review of Hematology</i> , 2019, 12, 937-945.	1.0	6
23	Bloodstream infections caused by <i>Escherichia coli</i> in onco-haematological patients: Risk factors and mortality in an Italian prospective survey. <i>PLoS ONE</i> , 2019, 14, e0224465.	1.1	27
24	Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management. <i>Medical Mycology</i> , 2019, 57, S127-S137.	0.3	14
25	Fungaemia in haematological malignancies: SEIFEM 2015 survey. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13083.	1.7	20
26	Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases. <i>Mycoses</i> , 2019, 62, 252-260.	1.8	54
27	Real-life analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1062-1068.	1.3	11
28	Rhodotorula infection in haematological patient: Risk factors and outcome. <i>Mycoses</i> , 2019, 62, 223-229.	1.8	17
29	Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study. <i>HemaSphere</i> , 2019, 3, e320.	1.2	8
30	Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting. <i>Bone Marrow Transplantation</i> , 2018, 53, 1304-1310.	1.3	12
31	Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL). <i>Annals of Hematology</i> , 2018, 97, 791-798.	0.8	10
32	SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders. <i>Expert Review of Hematology</i> , 2018, 11, 155-168.	1.0	4
33	Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1765-1770.	2.0	22
34	Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1699-1706.	2.0	33
35	Prophylaxis for aspergillosis in patients with haematological malignancies: pros and cons. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 531-542.	2.0	6
36	Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients. <i>Annals of Hematology</i> , 2018, 97, 2205-2215.	0.8	4

#	ARTICLE	IF	CITATIONS
37	Assesment of Frailty Scores Validating Fitness of Elderly AML Patients for Intensive Chemotherapy: A Single Centre Study. <i>Blood</i> , 2018, 132, 5171-5171.	0.6	2
38	Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients. <i>Expert Review of Hematology</i> , 2017, 10, 543-550.	1.0	14
39	SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 2859-2864.	0.6	6
40	Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use. <i>Journal of Chemotherapy</i> , 2017, 29, 131-143.	0.7	26
41	Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey. <i>Leukemia Research</i> , 2017, 53, 74-81.	0.4	37
42	In-vivo or ex-vivo T cell depletion or both to prevent graft-versus-host disease after hematopoietic stem cell transplantation. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1-15.	1.4	10
43	Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study. <i>Leukemia Research</i> , 2017, 61, 10-17.	0.4	18
44	Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report. <i>Haematologica</i> , 2017, 102, e407-e410.	1.7	17
45	Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. <i>Blood Reviews</i> , 2017, 31, 17-29.	2.8	98
46	Late-onset hepatic veno-occlusive disease after allografting: report of two cases with atypical clinical features successfully treated with defibrotide.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017, 10, 2018001.	0.5	2
47	Management of carbapenem-resistant <i>K. pneumoniae</i> in allogeneic stem cell transplant recipients: the Turin bundle. <i>New Microbiologica</i> , 2017, 40, 143-145.	0.1	6
48	Antifungal therapy in hematopoietic stem cell transplant recipients. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, e2016039.	0.5	12
49	Ruxolitinib in steroid refractory graft-vs.-host disease: a case report. <i>Journal of Hematology and Oncology</i> , 2016, 9, 67.	6.9	21
50	Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. <i>Expert Review of Hematology</i> , 2016, 9, 585-596.	1.0	51
51	Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2214-2219.	2.0	13
52	Bloodstream infections caused by <i>Klebsiella pneumoniae</i> in oncohematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. <i>American Journal of Hematology</i> , 2016, 91, 1076-1081.	2.0	115
53	Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 96-103.	0.2	1
54	The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors. <i>American Journal of Hematology</i> , 2015, 90, E117-21.	2.0	19

#	ARTICLE	IF	CITATIONS
55	Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the <sc>SEIFEM</sc> registry. British Journal of Haematology, 2015, 170, 434-439.	1.2	14
56	Efficacy of plasmapheresis for the treatment of pure red blood cell aplasia after allogeneic stem cell transplantation. Transfusion, 2015, 55, 2979-2982.	0.8	16
57	Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data. Journal of Chemotherapy, 2015, 27, 1-12.	0.7	19
58	Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). Haematologica, 2015, 100, 284-292.	1.7	64
59	Reviewing the importance and evolution of fungal infections and potential antifungal resistance in haematological patients. Journal of Global Antimicrobial Resistance, 2015, 3, 237-241.	0.9	11
60	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2015, 16, 1525-1536.	5.1	143
61	Genetic PTX3 Deficiency and Aspergillosis in Stem-Cell Transplantation. New England Journal of Medicine, 2014, 370, 421-432.	13.9	265
62	Allogeneic stem cell transplant for adults with myelodysplastic syndromes: relevance of pre-transplant disease status. Leukemia and Lymphoma, 2014, 55, 863-869.	0.6	4
63	Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles. Journal of Chemotherapy, 2014, 26, 315-320.	0.7	6
64	Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey. Journal of Antimicrobial Chemotherapy, 2014, 69, 3142-3147.	1.3	21
65	Primary Prophylaxis of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Revised Recommendations from a Consensus Process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biology of Blood and Marrow Transplantation, 2014, 20, 1080-1088.	2.0	54
66	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biology of Blood and Marrow Transplantation, 2014, 20, 872-880.	2.0	141
67	Second-Generation Tyrosine Kinase Inhibitors Can Induce Complete Molecular Response in Ph-Positive Acute Lymphoblastic Leukemia After Allogeneic Stem Cell Transplant. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S272-S275.	0.2	6
68	Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis. BMC Infectious Diseases, 2013, 13, 563.	1.3	39
69	A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Hematological Oncology, 2013, 31, 117-126.	0.8	21
70	Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica, 2013, 98, e127-e130.	1.7	99
71	Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B Registry. Clinical Infectious Diseases, 2012, 55, 1515-1521.	2.9	77
72	Derivation and Validation of a Scoring System to Identify Patients with Bacteremia and Hematological Malignancies at Higher Risk for Mortality. PLoS ONE, 2012, 7, e51612.	1.1	18

#	ARTICLE	IF	CITATIONS
73	The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 687-697.	1.4	16
74	Amphotericin B Lipid Complex in the Management of Invasive Fungal Infections in Immunocompromised Patients. <i>Clinical Drug Investigation</i> , 2011, 31, 745-758.	1.1	18
75	In vivo T cell depletion with pretransplant low-dose antithymocyte globulin is associated with reduced transplant-related mortality and improved clinical outcome in patients receiving allogeneic hematopoietic stem cell transplantation from unrelated and partially matched related donors. <i>American Journal of Hematology</i> , 2011, 86, 214-217.	2.0	8
76	Multidrug resistant <i>Pseudomonas aeruginosa</i> bloodstream infection in adult patients with hematologic malignancies. <i>Haematologica</i> , 2011, 96, e1-e3.	1.7	67
77	Combined antifungal therapy, iron chelation and surgical resection as treatment of hepatic zygomycosis in a patient with haematological malignancy. <i>Mycoses</i> , 2010, 53, 275-278.	1.8	25
78	Iron Overload in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: Quantification of Iron Burden by a Superconducting Quantum Interference Device (SQUID) and Therapeutic Effectiveness of Phlebotomy. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 115-122.	2.0	57
79	Mesenchymal Stem Cell-Derived Microvesicles Protect Against Acute Tubular Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1053-1067.	3.0	1,144
80	Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogeneic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 600-608.	1.3	55
81	Cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation: significant progress, but many unresolved problems. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 383-385.	1.4	5
82	Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. <i>Blood</i> , 2009, 113, 3375-3382.	0.6	92
83	Human Mesenchymal Stem Cells Inhibit Neutrophil Apoptosis: A Model for Neutrophil Preservation in the Bone Marrow Niche. <i>Stem Cells</i> , 2008, 26, 151-162.	1.4	442
84	Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2007, 82, 45-52.	2.0	150
85	Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: Results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial. <i>American Journal of Hematology</i> , 2007, 82, 863-866.	2.0	22
86	Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. <i>European Journal of Haematology</i> , 2007, 78, 330-337.	1.1	25
87	Risk Factors and Severe Outcome in Thrombotic Microangiopathy After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2006, 82, 638-644.	0.5	144
88	Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors. <i>Hematology</i> , 2006, 11, 171-177.	0.7	2
89	Chronic graft-versus-host disease after reduced-intensity stem cell transplantation versus conventional hematopoietic stem cell transplantation. <i>Hematology</i> , 2005, 10, 1-10.	0.7	10
90	Posttransplantation chronic renal damage in nonrenal transplant recipients. <i>Kidney International</i> , 2005, 68, 1453-1463.	2.6	51

#	ARTICLE	IF	CITATIONS
91	Sirolimus-Related Toxicity in Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 647-649.	2.0	14
92	Treatment of Severe Refractory Acute Graft-versus-Host Disease of the Gastrointestinal Tract with Campath-1H. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 734-736.	2.0	17
93	Acute Hepatitis-Like Presentation of Graft-versus-Host Disease following Donor Lymphocyte Infusion. <i>Acta Haematologica</i> , 2003, 110, 48-50.	0.7	0
94	Immune Reconstitution and Early Infectious Complications Following Nonmyeloablative Hematopoietic Stem Cell Transplantation. <i>Hematology</i> , 2003, 8, 303-311.	0.7	30
95	Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection. <i>Blood</i> , 2003, 102, 773-774.	0.6	39
96	Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. <i>Haematologica</i> , 2003, 88, 837-9.	1.7	36
97	Bone Marrow Transplant Associated Thrombotic Microangiopathy. <i>Hematology</i> , 2000, 5, 53-67.	0.7	15
98	Recent Advances in Bone Marrow Transplantation from Unrelated Volunteer Donors. <i>Hematology</i> , 1996, 1, 3-17.	0.7	1
99	Cutaneous Relapse in a Child with Acute Mixed Leukemia. <i>Pediatric Hematology and Oncology</i> , 1993, 10, 85-88.	0.3	0
100	Unique genotypic features of infant acute lymphoblastic leukaemia at presentation and at relapse. <i>British Journal of Haematology</i> , 1992, 80, 472-479.	1.2	23